Why the study?
Do intranasal antiviral compounds (SKF 40491, GLR9-338, or RP L9326) reduce virus shedding and clinical symptoms in volunteers challenged with rhinovirus?
Do intranasal antiviral compounds (SKF 40491, GLR9-338, or RP L9326) reduce virus shedding and clinical symptoms in volunteers challenged with rhinovirus?
Intranasal administration of GLR9-338 and RP L9326 significantly reduced rhinovirus shedding in challenged volunteers, with RP L9326 also reducing clinical symptom severity.
Answers are grounded in this paper and cite their sources.
May limit rhinovirus spread and illness in exposed persons; supports further trials of intranasal antivirals beyond challenge studies.
Four unrelated compounds active against rhinovirus were compared in tissue culture, and three of them were used in volunteers challenged with rhinovirus. The compounds were the triazino-indole SKF 40491, the substituted oxadiazole GLR9-338, the imidazo-thiazole RP L9326, and the guanidine derivative ICI 73,602. The abilities of these compounds to reduce the yield of rhinovirus types 3, 4, 9, and 31 from HeLa cells or fibroblasts were compared, and a sensitive serotype was chosen for each challenge experiment in humans. In doubleblind studies volunteers received intranasal medication before and after the challenge. Daily scoring of symptoms and titration of virus in nasal washings showed that subjects treated with SKF, GL, and RP all shed less virus than their corresponding placebo groups, significantly so in the cases of GL and RP. Clinical reactions were also less severe in volunteers treated with RP.
No takes yet. Share an insight, caveat, or question.
Reed et al. (1976) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: